IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting
10. Dezember 2024 07:00 ET
|
IN8bio, Inc
IN8bio Reports Continued Progression-Free Survival in Phase 1 Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 ASH Conference
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia
06. Dezember 2024 08:00 ET
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
03. Dezember 2024 07:30 ET
|
Aptose Biosciences, Inc.
Aptose's AML drug tuspetinib selected for NCI's prestigious clinical research program for ability to target broad spectrum of AML and MDS populations
ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Annual Meeting
26. November 2024 05:00 ET
|
ImCheck Therapeutics SAS
ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Annual Meeting Marseille, France, November 26, 2024, 11 am CET –...
9-Year Old Rare Blood Disorder Survivor Meets Lifesaving Donor at Gift of Life Marrow Registry Gala
22. November 2024 15:37 ET
|
Gift of Life Marrow Registry
Miami Beach Event Honored Emilio Estefan, Jr., Vice Mayor Alex Fernandez and Boucher Brothers for their Distinguished Advocacy BOCA RATON, Fla., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Gift of Life...
First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach
21. November 2024 05:07 ET
|
Pentixapharm Holding AG
BERLIN and WURZBURG, Germany, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pentixapharm Holding AG, a biopharmaceutical company developing innovative first-in-class radiopharmaceuticals, today announced that...
Understanding the United States Chronic Lymphocytic Leukemia (CLL) Patient Journey to Make Informed Business Decisions, Identify Opportunities, and Understand Potential Challenges
25. Oktober 2024 04:07 ET
|
Research and Markets
Dublin, Oct. 25, 2024 (GLOBE NEWSWIRE) -- The "Chronic Lymphocytic Leukemia (CLL) in the United States: Understanding the CLL Patient Experience" report has been added to ResearchAndMarkets.com's...
Understanding the United States Chronic Myeloid Leukemia (CML) Patient Experience to Make Informed Business Decisions, Identify Opportunities, and Understand Potential Challenges
25. Oktober 2024 04:06 ET
|
Research and Markets
Dublin, Oct. 25, 2024 (GLOBE NEWSWIRE) -- The "Chronic Myeloid Leukemia (CML) in the United States: Understanding the CML Patient Experience" report has been added to ResearchAndMarkets.com's...
United States Chronic Myeloid Leukemia (CML) Patient Quality of Life & Information-Seeking Behaviors Insights Report 2024
24. Oktober 2024 04:25 ET
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Chronic Myeloid Leukemia (CML) in the United States: Quality of Life & Information-Seeking Behaviors" report has been added to ...
Smart Immune détermine la dose recommandée de SMART101 pour ses essais cliniques en oncologie
23. Oktober 2024 01:01 ET
|
Smart Immune
La phase I d'escalade de dose de ReSET-02 chez des adultes souffrant de cancers hématologiques est terminée.Le segment randomisé de la phase II de cet essai est en cours.Aucune toxicité limitant la...